METHOD AND DEVICE FOR CARDIOSYMPATHETIC INHIBITION

• US 20080249584A1
• Filed: 04/05/2007
• Published: 10/09/2008
• Est. Priority Date: 04/05/2007
• Status: Abandoned Application

• Current Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Original Assignee: Cardiac Pacemakers Incorporated (Boston Scientific Corporation)
• Inventors: Scheurer, Elizabeth Swanhild
• Application Number:
  US11/696,923
• Publication Number:
  US 20080249584A1
• Time in Patent Office: Days
• US Class Current: 607/14
• CPC Class Codes: A61N 1/0553 Paddle shaped electrodes, e.g. for laminotomy
• CPC Class Codes: A61N 1/36114 Cardiac control, e.g. by vagal stimulation stimulating the heart A61N1/362
• CPC Class Codes: A61N 1/39622 Pacing therapy

Abstract

Described herein are methods and devices that utilize electrical neural stimulation for inhibiting cardiosympathetic activity in order to reduce the risk of sudden cardiac death. In one embodiment, one or more stimulating electrodes are disposed near the left stellate ganglion. An implantable pulse generator delivers neural stimulation to the electrodes in a manner that inhibits activity of the ganglionic tissue.

Claims

1. An implantable device, comprising:

a pulse generator for outputting neural stimulation pulses;

one or more stimulation electrodes connected to the pulse generator for delivering electrical stimulation to a selected neural site, wherein the stimulation electrodes are adapted for disposition near the left stellate ganglion of a patient;

a controller connected to the pulse generator for controlling the output of neural stimulation pulses in a manner that inhibits cardiosympathetic activity by acting on the left stellate ganglion;

wherein the controller is programmed to neural stimulation pulses according to a duty cycle that alternates between a neural stimulation state and a non-neural stimulation state in accordance with one or more defined entry and exit conditions;

one or more sensors connected to the controller for sensing one or more physiological variables related to an increased risk of sudden cardiac death; and

,

wherein the controller is programmed to transition to the neural stimulation state and deliver neural stimulation that inhibits cardiosympathetic activity according to an entry condition defined as when the one or more physiological variables indicate that the patient is at increased risk for sudden cardiac death.

2. The device of claim 1 wherein the one or more sensors include a sensor for measuring a physiological variable selected from a group consisting of heart rate, PR interval, minute ventilation, activity level, blood pressure, myocardial ischemia, and heart rate variability.

3. The device of claim 1 further comprising a patient-operated switch and wherein the defined entry and exit conditions include receipt of a command via the patient-operated switch to enter or exit the neural stimulation state.

4. The device of claim 1 further comprising a telemetry transceiver and wherein the defined entry and exit conditions include receipt of a command via the telemetry transceiver to enter or exit the neural stimulation state.

5. The device of claim 1 wherein the defined entry and exit conditions include conditions selected from a group consisting of a lapsed time interval, detection or non-detection of the presence of myocardial ischemia by the device in accordance with a sensed variable that is correlated with the presence of myocardial ischemia such as features derived from sensed cardiac electrical activity, or a sensed physiological variable being below or above a specified threshold value.

6. The device of claim 1 wherein the one or more stimulation electrodes further comprises a grid array incorporating a plurality of stimulation electrodes connectable to the pulse generator by a switch matrix for delivering electrical stimulation to a selected neural site, wherein the grid array is adapted for disposition near the left stellate ganglion of a patient.

7. The device of claim 1 wherein the pulse generator may be adjusted to output neural stimulation pulses as biphasic pulses at a specified amplitude and frequency to optimally block cardiosympathetic activity in accordance with empirical data derived from clinical testing.

8. An implantable device, comprising:

a pulse generator for outputting neural stimulation pulses;

a grid array incorporating a plurality of stimulation electrodes connectable to the pulse generator for delivering electrical stimulation to a selected neural site, wherein the grid array is adapted for disposition near the left stellate ganglion of a patient;

a controller connected to the pulse generator for controlling the output of neural stimulation pulses in a manner that inhibits cardiosympathetic activity by acting on the left stellate ganglion;

a telemetry transceiver interfaced to the controller; and

,

wherein the controller is programmed to configure neural stimulation channels with one or more electrodes of the grid array by operating a switch matrix in accordance with commands received via the telemetry transceiver.

9. The device of claim 8 wherein the switch matrix may be operated to configure one or more neural stimulation channels that optimally block cardiosympathetic activity in accordance with empirical data derived from clinical testing.

10. The device of claim 8 wherein the pulse generator may be adjusted to output neural stimulation pulses as biphasic pulses at a specified amplitude and frequency to optimally block cardiosympathetic activity in accordance with empirical data derived from clinical testing.

11. The device of claim 8 further comprising:

one or more sensors connected to the controller for sensing one or more physiological variables related to a patient'"'"'s sympathetic activity; and

,

wherein the controller is programmed to increase the amount of inhibitory neural stimulation if one or more physiological variables indicates that the patient'"'"'s sympathetic activity is above a specified threshold value.

12. A method, comprising:

implanting a pulse generator connected to one or more neural stimulation electrodes;

implanting the one or more stimulation electrodes near the left stellate ganglion of a patient; and

,

delivering neural stimulation pulses from the pulse generator to the left stellate ganglion in a manner that inhibits cardiosympathetic activity.

13. The method of claim 12 wherein the one or more stimulation electrodes is a plurality of electrodes incorporated into grid array and further comprising:

configuring different neural stimulation channels by selectively connecting electrodes of the grid array to the pulse generator via operation of a switch matrix;

testing different neural stimulation channels for efficacy in inhibiting cardiosympathetic activity by delivering neural stimulation pulses to the left stellate ganglion; and

,

selecting a neural stimulation channel configured with an electrode of the grid array that optimally inhibits cardiosympathetic activity.

14. The method of claim 12 further comprising configuring the pulse generator to deliver neural stimulation for inhibiting cardiosympathetic activity on a continuous basis.

15. The method of claim 12 further comprising configuring the pulse generator to deliver neural stimulation for inhibiting cardiosympathetic activity on an intermittent basis in accordance with defined entry and exit conditions.

16. The method of claim 15 wherein the defined entry and exit conditions include conditions selected from a group consisting of a lapsed time interval, detection or non-detection of the presence of myocardial ischemia by the device in accordance with a sensed variable that is correlated with the presence of myocardial ischemia such as features derived from sensed cardiac electrical activity, or a sensed physiological variable being below or above a specified threshold value.

17. The method of claim 12 further comprising selecting a particular neural stimulation waveform for inhibiting cardiosympathetic activity in accordance with clinical testing.

18. The method of claim 12 further comprising selecting a particular neural stimulation amplitude for inhibiting cardiosympathetic activity in accordance with clinical testing.

19. The method of claim 12 further comprising selecting a particular neural stimulation frequency for inhibiting cardiosympathetic activity in accordance with clinical testing.

20. The method of claim 12 wherein the neural stimulation is delivered as biphasic pulses at a frequency between 350 Hz and 12.5 kHz.